Septerna, Inc. Price & Performance (SEPN)

Septerna, Inc. is under investigation by the Schall Law Firm following its decision to discontinue a Phase 1 clinical trial for SEP-786. The trial was halted due to severe bilirubin elevations in participants. This led to a nearly 47% stock drop, raising concerns about potential misleading disclosures to investors.12

Recent insider transactions at Septerna, Inc. reveal strong confidence among executives. CEO Jeffrey Finer and CFO Gil Labrucherie collectively acquired over $260,000 worth of shares. Despite a 70% stock decline over the past year, analysts maintain optimistic price targets, emphasizing the company’s long-term growth potential.34

Septerna director Alan Ezekowitz recently purchased $515,934 in company shares, increasing his holdings to over 104,000 shares. The transactions occurred as the stock fell over 70% in six months. Analysts remain optimistic, citing the company’s pipeline and financial stability despite recent setbacks.56